Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy KalVista Pharmaceuticals (KALV) stocks in Canada

Learn how to easily invest in KalVista Pharmaceuticals stocks.

KalVista Pharmaceuticals is a biotechnology business based in the US. KalVista Pharmaceuticals stocks (KALV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23 – a decrease of 1.75% over the previous week. KalVista Pharmaceuticals employs 70 staff and has a trailing 12-month revenue of around $3.8 million.

How to buy shares in KalVista Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KALV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

KalVista Pharmaceuticals stock price (NASDAQ:KALV)

Use our graph to track the performance of KALV stocks over time.

KalVista Pharmaceuticals shares at a glance

Information last updated 2022-01-17.
Latest market close$11.77
52-week range$11.65 - $45.00
50-day moving average $14.61
200-day moving average $20.33
Wall St. target price$51.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.72

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy KalVista Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

KalVista Pharmaceuticals price performance over time

Historical closes compared with the close of $11.77 from 2022-01-19

1 week (2022-01-13) -1.75%
1 month (2021-12-17) -10.83%
3 months (2021-10-20) -32.67%
6 months (2021-07-20) -46.21%
1 year (2021-01-20) -27.52%
2 years (2020-01-17) -36.58%
3 years (2019-01-18) 16.71
5 years (2017-01-20) 61.23%

KalVista Pharmaceuticals financials

Revenue TTM $3.8 million
Gross profit TTM $-41,286,000
Return on assets TTM -28.9%
Return on equity TTM -41.55%
Profit margin 0%
Book value $9.31
Market capitalisation $306.9 million

TTM: trailing 12 months

KalVista Pharmaceuticals share dividends

We're not expecting KalVista Pharmaceuticals to pay a dividend over the next 12 months.

Have KalVista Pharmaceuticals's shares ever split?

KalVista Pharmaceuticals's shares were split on a 1:14 basis on 21 November 2016. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KalVista Pharmaceuticals shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for KalVista Pharmaceuticals shares which in turn could have impacted KalVista Pharmaceuticals's share price.

KalVista Pharmaceuticals share price volatility

Over the last 12 months, KalVista Pharmaceuticals's shares have ranged in value from as little as $11.65 up to $45. A popular way to gauge a stock's volatility is its "beta".

KALV.US volatility(beta: 1.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KalVista Pharmaceuticals's is 1.9417. This would suggest that KalVista Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

KalVista Pharmaceuticals overview

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts. .

Stocks similar to KalVista Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site